Invited Editorial: Advantages and Limitations of FAERS in Assessing Adverse Event Reporting for Eluxadoline

Antzeko izenburuak

• Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
  nork: Zhuomiao Lin, et al.
  Argitaratua: (2025-08-01)
• Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
  nork: Yuzhe Cheng, et al.
  Argitaratua: (2025-01-01)
• Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
  nork: Yuzhe Cheng, et al.
  Argitaratua: (2025-01-01)
• A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
  nork: Yun Li, et al.
  Argitaratua: (2025-01-01)
• Drug Profile Elobixibat for the Treatment of Constipation
  nork: Chedid, Victor, et al.
  Argitaratua: (2018)